Omega-3 Fatty Acids for Perimenopause: Multi-System Brain and Body Support

EPA is the primary omega-3 involved in resolving inflammation. It is metabolized into Series 3 prostaglandins and specialized pro-resolving mediators (SPMs) that actively switch off inflammatory cascades — not merely blocking them like NSAIDs but actively resolving them. During perimenopause, the loss of estrogen's anti-inflammatory signaling unleashes systemic inflammation that EPA directly addresses. More specifically for mood: EPA inhibits the kynurenine pathway, which converts tryptophan into inflammatory compounds (instead of serotonin) during inflammation. Multiple meta-analyses show EPA-dominant omega-3 supplements reduce depression scores comparably to antidepressants for mild-to-moderate depression, making EPA the most evidence-based nutritional antidepressant available.

DHA is a structural component of neuronal cell membranes — it constitutes approximately 15–20% of the brain's total fatty acid content. It maintains membrane fluidity in the synaptic cleft, supports the function of membrane-bound receptors (serotonin, dopamine, acetylcholine), and is required for the efficient function of ion channels that generate neural signals. During perimenopause, as estrogen's membrane-supporting effects decline, adequate DHA is essential for maintaining the neuronal membrane quality that supports fast, efficient neural communication. DHA is also preferentially incorporated into retinal cells, and perimenopausal women frequently notice visual changes — DHA supplementation supports visual clarity as well as cognitive performance.

For anti-inflammatory and mood benefits, EPA-dominant formulas (≥60% EPA) at 2–3g EPA+DHA combined are most effective. For cognitive/brain structure support, balanced EPA:DHA ratios are appropriate. Quality is paramount: omega-3s oxidize easily, producing inflammatory aldehydes that counteract benefits — look for IFOS-certified products with oxidation markers below TOTOX 26 and proof of third-party testing. Triglyceride form (rather than ethyl ester form) is 70% better absorbed. Take with the largest meal of the day. Effects on mood and inflammation become measurable at 8 weeks; full anti-inflammatory benefit develops over 12 weeks. Significant drug interactions: high-dose omega-3 (>3g/day) has mild antiplatelet effects — caution with warfarin.